VVVictor Rezende Veras

Victor Rezende Veras

*This is an algorithmically generated author record based on publicly available information.

Victor Rezende Veras has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Calf skinfold measurements as a diagnostic tool for lipodystrophy syndromes: a cross-sectional study

    by Grayce Ellen da Cruz Paiva Lima, Fabia Karine de Moura Lopes, Jessica Silveira Araújo, Natália Prado Boris, Virginia Oliveira Fernandes, Victor Rezende Veras, Mayara Teixeira Alexandrino Sales, Lorena Taúsz Tavares Ramos, Amanda Caboclo Flor, Ana Paula Dias Rangel Montenegro, et al.

    Background: Lipodystrophy syndromes (LS) are characterized by reduced body fat and associated metabolic complications, such as insulin resistance and diabetes. The diagnosis of LS can be challenging in clinical settings. Skinfold measurement and body composition assessment using DEXA are commonly used for screening and diagnosis. This study aimed to identify alternative easy-to-use body composition parameters for diagnosing LS in clinical settings. Methods: This cross-sectional study included patients with genetically confirmed congenital generalized lipodystrophy (CGL) and familial partial lipodystrophy (FPL), with 62 matched healthy controls. Comprehensive data, including medical history, body composition, laboratory measurements, and imaging parameters, were collected. The receiver operating characteristic (ROC) curve was constructed using genetic test results, the gold standard for diagnosing genetic lipodystrophy, as the reference, and the sensitivity and specificity of calf skinfold measurements were measured with those of the genetic tests. Results: We included 62 patients with a mean age of 32 ± 18 (2–68) years, of whom 69.3% were women. The prevalence of diabetes mellitus (70%) and hypertriglyceridemia (83%) were also high. All body composition parameters significantly differed, except for calf skinfold measurements, which were similar between the CGL and FPL patients (p = 0.270). The ROC curve analysis identified a new cutoff point for calf skinfold measurement of <8 mm, with high diagnostic accuracy. Conclusions: This study identified calf skinfold measurements <8 mm as an accurate diagnostic tool for CGL and FPL. Notably, clinical accessibility to calf skinfold will favor its widespread use, standardization, and inclusion in physical examination protocols, improving lipodystrophy detection and diagnosis.

  • Open Access

    Anthropometric measurements as a key diagnostic tool for familial partial lipodystrophy in women

    by Victor Rezende Veras, Grayce Ellen da Cruz Paiva Lima, Ivana da Ponte Melo, Virginia Oliveira Fernandes, Fabia Karine de Moura Lopes, Camila Lopes Do Amaral, Maria Helane Gurgel Castelo, Larissa Luna Queiroz, Jessica Silveira Araújo, Cynthia Melissa Valerio, et al.

    Background: Familial Partial Lipodystrophy (FPLD) is a disease with wide clinical and genetic variation, with seven different subtypes described. Until genetic testing becomes feasible in clinical practice, non-invasive tools are used to evaluate body composition in lipodystrophic patients. This study aimed to analyze the different anthropometric parameters used for screening and diagnosis of FPLD, such as thigh skinfold thickness (TS), Köb index (Köbi), leg fat percentage (LFP), fat mass ratio (FMR) and leg-to-total fat mass ratio in grams (LTR), by dual-energy X-ray absorptiometry, focusing on determining cutoff points for TS and LFP within a Brazilian population. Methods: Thirty-seven patients with FPLD and seventy-four healthy controls matched for body mass index, sex and age were studied. Data were collected through medical record review after signing informed consent. All participants had body fat distribution evaluated by skinfolds and DXA measures. Fasting blood samples were collected to evaluate glycemic and lipid profiles. Genetic studies were carried out on all patients. Two groups were categorized based on genetic testing and/or anthropometric characteristics: FPLD+ (positive genetic test) and FPLD1 (negative genetic testing, but positive clinical/anthropometric criteria for FPLD). Results: Eighteen (48.6%) patients were classified as FPLD+, and 19 (51.4%) as FPLD1. Unlike what is described in the literature, the LMNA variant in codon 582 was the most common. Among the main diagnostic parameters of FPLD, a statistical difference was observed between the groups for, Köbi, TS, LFP, FMR, and LTR. A cutoff point of 20 mm for TS in FPLD women was found, which is lower than the value classically described in the literature for the diagnosis of FPLD. Additionally, an LFP < 29.6% appears to be a useful tool to aid in the diagnosis of these women. Conclusion: Combining anthropometric measurements to assess body fat distribution can lead to a more accurate diagnosis of FPLD. This study suggests new cutoff points for thigh skinfold and leg fat percentage in women with suspected FPLD in Brazil. Further studies are needed to confirm these findings.


  • Open Access

    Evaluation of the anti-diabetic drug sitagliptin as a novel attenuate to SARS-CoV-2 evidence-based in silico: molecular docking and molecular dynamics

    by José Ednésio da Cruz Freire, José Edvar Monteiro Júnior, Daniel Pascoalino Pinheiro, Grayce Ellen da Cruz Paiva Lima, Camila Lopes Do Amaral, Victor Rezende Veras, Mayara Ponte Madeira, Erika Bastos Lima Freire, Renan Galvão Ozório, Virgínia Oliveira Fernandes, et al.

    The current outbreak of COVID-19 cases worldwide has been responsible for a significant number of deaths, especially in hospitalized patients suffering from comorbidities, such as obesity, diabetes, hypertension. The disease not only has prompted an interest in the pathophysiology, but also it has propelled a massive race to find new anti-SARS-CoV-2 drugs. In this scenario, known drugs commonly used to treat other diseases have been suggested as alternative or complementary therapeutics. Herein we propose the use of sitagliptin, an inhibitor of dipeptidyl peptidase-4 (DPP4) used to treat type-II diabetes, as an agent to block and inhibit the activity of two proteases, 3CLpro and PLpro, related to the processing of SARS-CoV-2 structural proteins. Inhibition of these proteases may possibly reduce the viral load and infection on the host by hampering the synthesis of new viruses, thus promoting a better outcome. In silico assays consisting in the modeling of the ligand sitagliptin and evaluation of its capacity to interact with 3CLpro and PLpro through the prediction of the ligand bioactivity, molecular docking, overlapping of crystal structures, and molecular dynamic simulations were conducted. The experiments indicate that sitagliptin can interact and bind to both targets. However, this interaction seems to be stronger and more stable to 3CLpro (ΔG = −7.8 kcal mol−1), when compared to PLpro (ΔG = −7.5 kcal mol−1). This study suggests that sitagliptin may be suitable to treat COVID-19 patients, beyond its common use as an anti-diabetic medication. In vivo studies may further support this hypothesis.